N/A
Completed N=278
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
Source: ClinicalTrials.gov NCT00736502 ↗Enrolled (actual)
278
Serious AEs
4.3%
Results posted
Aug 2012
Primary outcomePrimary: Proportion of Patients Reporting Adverse Events — 25.5; 4.3; 9.7; 3.2 Percentage of participants
Summary
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients Reporting Adverse Events |
25.5; 4.3; 9.7; 3.2; 3.2; 3.6 | — |
| SECONDARY Virologic Response (VR) |
139; 16; 123 | — |
| SECONDARY Change in CD4+ Cell Count From Baseline to Week 48 |
148.5 | — |
Eligibility Criteria
Inclusion criteria
The inclusion criteria follow the same criteria which are describe in the newest SPC.
Exclusion criteria
The exclusion criteria follow the same criteria which are describe in the newest SPC.
Data sourced from ClinicalTrials.gov (NCT00736502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.